Anesthesia

Your Article Summary

See Latest Articles

Pregabalin: In the Treatment of Postherpetic Neuralgia
Drugs & Aging, 09/21/09

McKeage K et al. – Pregabalin is the pharmacologically active S–enantiomer of 3–aminomethyl–5–methyl–hexanoic acid. It has a similar pharmacological profile to that of its developmental predecessor gabapentin, but had greater analgesic activity in rodent models of neuropathic pain.

• Oral pregabalin 150–600 mg/day, administered in two or three divided doses, was significantly more effective than placebo in relieving pain and improving pain–related sleep interference in four randomized, double–blind, multicentre studies of 4–13 weeks' duration in patients with postherpetic neuralgia (PHN).
• Pregabalin achieved a faster onset of pain relief than placebo. The median times to the onset of pain relief with fixed and flexible doses of pregabalin were 1.5 and 3.5 days compared with >4 weeks with placebo.
• Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity.

Today in Pain Management...keeping you current

Receive free subspecialty "5-minute updates" via email

Pediatric Pain After Ambulatory Surgery: Where's the Medication?
Pediatrics, 10/01/09

Epidural Analgesia in the Latent Phase of Labor and the Risk of Cesarean Delivery: A Five-year Randomized Controlled Trial
Anesthesiology, 09/11/09

Use of oral ketamine in chronic pain management: A review
European Journal of Pain, 11/02/09

See All of Pain Management